vs
LXP Industrial Trust（LXP）与MIMEDX GROUP, INC.（MDXG）财务数据对比。点击上方公司名可切换其他公司
MIMEDX GROUP, INC.的季度营收约是LXP Industrial Trust的1.4倍（$118.1M vs $86.7M），LXP Industrial Trust净利率更高（33.2% vs 12.9%，领先20.3%），MIMEDX GROUP, INC.同比增速更快（27.1% vs -14.0%），过去两年MIMEDX GROUP, INC.的营收复合增速更高（18.1% vs 0.3%）
LXP工业信托是一家公开上市的房地产投资信托，专注于持有、运营和投资美国核心市场的优质工业地产，主要涵盖配送中心、物流设施及轻型工业物业，服务电商、第三方物流、先进制造等领域租户，为投资者创造长期稳定收益。
MiMedx是一家总部位于美国佐治亚州玛丽埃塔的生物医疗企业，成立于2008年。该企业以胎盘、羊膜囊、脐带等分娩组织为原料，开发可用于植皮手术的医用真皮产品，在生物再生医疗领域开展业务。
LXP vs MDXG — 直观对比
营收规模更大
MDXG
是对方的1.4倍
$86.7M
营收增速更快
MDXG
高出41.1%
-14.0%
净利率更高
LXP
高出20.3%
12.9%
两年增速更快
MDXG
近两年复合增速
0.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $86.7M | $118.1M |
| 净利润 | $28.8M | $15.2M |
| 毛利率 | 81.5% | 83.9% |
| 营业利润率 | 34.6% | 17.8% |
| 净利率 | 33.2% | 12.9% |
| 营收同比 | -14.0% | 27.1% |
| 净利润同比 | — | 104.2% |
| 每股收益（稀释后） | — | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LXPMDXG
| Q4 25 | $86.7M | $118.1M | ||
| Q3 25 | $86.9M | $113.7M | ||
| Q2 25 | $87.7M | $98.6M | ||
| Q1 25 | $88.9M | $88.2M | ||
| Q4 24 | $100.9M | $92.9M | ||
| Q3 24 | $85.6M | $84.1M | ||
| Q2 24 | $85.8M | $87.2M | ||
| Q1 24 | $86.3M | $84.7M |
净利润LXPMDXG
| Q4 25 | $28.8M | $15.2M | ||
| Q3 25 | $36.3M | $16.7M | ||
| Q2 25 | $29.1M | $9.6M | ||
| Q1 25 | $19.0M | $7.0M | ||
| Q4 24 | — | $7.4M | ||
| Q3 24 | $6.3M | $8.1M | ||
| Q2 24 | $5.4M | $17.6M | ||
| Q1 24 | $-269.0K | $9.3M |
毛利率LXPMDXG
| Q4 25 | 81.5% | 83.9% | ||
| Q3 25 | 82.3% | 83.5% | ||
| Q2 25 | 81.9% | 81.1% | ||
| Q1 25 | 80.7% | 81.2% | ||
| Q4 24 | 85.3% | 81.8% | ||
| Q3 24 | 82.5% | 81.8% | ||
| Q2 24 | 82.0% | 83.0% | ||
| Q1 24 | 82.4% | 84.7% |
营业利润率LXPMDXG
| Q4 25 | 34.6% | 17.8% | ||
| Q3 25 | 50.4% | 19.5% | ||
| Q2 25 | 33.7% | 12.5% | ||
| Q1 25 | 21.8% | 9.4% | ||
| Q4 24 | — | 11.9% | ||
| Q3 24 | 7.9% | 13.3% | ||
| Q2 24 | 6.9% | 26.9% | ||
| Q1 24 | 1.0% | 15.6% |
净利率LXPMDXG
| Q4 25 | 33.2% | 12.9% | ||
| Q3 25 | 41.7% | 14.7% | ||
| Q2 25 | 33.2% | 9.8% | ||
| Q1 25 | 21.4% | 8.0% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | 7.4% | 9.6% | ||
| Q2 24 | 6.3% | 20.2% | ||
| Q1 24 | -0.3% | 10.9% |
每股收益（稀释后）LXPMDXG
| Q4 25 | — | $0.10 | ||
| Q3 25 | $0.12 | $0.11 | ||
| Q2 25 | $0.09 | $0.06 | ||
| Q1 25 | $0.06 | $0.05 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | $0.02 | $0.05 | ||
| Q2 24 | $0.01 | $0.12 | ||
| Q1 24 | $-0.01 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $170.4M | $166.1M |
| 总债务越低越好 | $1.4B | $18.0M |
| 股东权益账面价值 | $2.0B | $256.5M |
| 总资产 | $3.5B | $342.7M |
| 负债/权益比越低杠杆越低 | 0.66× | 0.07× |
8季度趋势，按日历期对齐
现金及短期投资LXPMDXG
| Q4 25 | $170.4M | $166.1M | ||
| Q3 25 | $229.7M | $142.1M | ||
| Q2 25 | $71.0M | $118.9M | ||
| Q1 25 | $70.9M | $106.4M | ||
| Q4 24 | $101.8M | $104.4M | ||
| Q3 24 | $55.0M | $88.8M | ||
| Q2 24 | $48.7M | $69.0M | ||
| Q1 24 | $293.8M | $48.5M |
总债务LXPMDXG
| Q4 25 | $1.4B | $18.0M | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.6B | $19.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LXPMDXG
| Q4 25 | $2.0B | $256.5M | ||
| Q3 25 | $2.1B | $238.9M | ||
| Q2 25 | $2.1B | $216.6M | ||
| Q1 25 | $2.1B | $202.8M | ||
| Q4 24 | $2.1B | $193.1M | ||
| Q3 24 | $2.1B | $181.0M | ||
| Q2 24 | $2.1B | $168.0M | ||
| Q1 24 | $2.2B | $155.7M |
总资产LXPMDXG
| Q4 25 | $3.5B | $342.7M | ||
| Q3 25 | $3.7B | $319.0M | ||
| Q2 25 | $3.7B | $291.1M | ||
| Q1 25 | $3.8B | $270.4M | ||
| Q4 24 | $3.8B | $263.9M | ||
| Q3 24 | $3.9B | $243.9M | ||
| Q2 24 | $3.9B | $230.2M | ||
| Q1 24 | $4.2B | $221.7M |
负债/权益比LXPMDXG
| Q4 25 | 0.66× | 0.07× | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | 0.10× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $188.7M | $25.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 6.56× | 1.64× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流LXPMDXG
| Q4 25 | $188.7M | $25.0M | ||
| Q3 25 | $63.5M | $29.3M | ||
| Q2 25 | $44.3M | $14.4M | ||
| Q1 25 | $39.0M | $5.3M | ||
| Q4 24 | $211.2M | $18.8M | ||
| Q3 24 | $64.6M | $19.6M | ||
| Q2 24 | $38.5M | $21.8M | ||
| Q1 24 | $38.9M | $6.0M |
现金转化率LXPMDXG
| Q4 25 | 6.56× | 1.64× | ||
| Q3 25 | 1.75× | 1.75× | ||
| Q2 25 | 1.52× | 1.50× | ||
| Q1 25 | 2.05× | 0.75× | ||
| Q4 24 | — | 2.53× | ||
| Q3 24 | 10.18× | 2.42× | ||
| Q2 24 | 7.09× | 1.24× | ||
| Q1 24 | — | 0.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LXP
暂无分部数据
MDXG
| Wound | $78.7M | 67% |
| Surgical | $39.4M | 33% |
